No correlation between COMT genotype and entacapone benefits in Parkinson's disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ji Seon | - |
dc.contributor.author | Kim, Ji-Young | - |
dc.contributor.author | Kim, Jong-Min | - |
dc.contributor.author | Kim, Jae Woo | - |
dc.contributor.author | Chung, Sun Ju | - |
dc.contributor.author | Kim, Sung R. | - |
dc.contributor.author | Kim, Mi J. | - |
dc.contributor.author | Kim, Hee-Tae | - |
dc.contributor.author | Choi, Kyoung-Gyu | - |
dc.contributor.author | Shin, Dong-Ick | - |
dc.contributor.author | Sung, Young Hee | - |
dc.contributor.author | Lee, Kwang-Soo | - |
dc.contributor.author | Kim, Han-Joon | - |
dc.contributor.author | Cho, Jinwhan | - |
dc.contributor.author | Park, Mee Young | - |
dc.contributor.author | Park, Hyun-Young | - |
dc.contributor.author | Choi, Seong-Min | - |
dc.contributor.author | Park, Kun-Woo | - |
dc.contributor.author | Lee, Ho-Won | - |
dc.contributor.author | Ahn, Tae-Beom | - |
dc.contributor.author | Kwon, Oh Dae | - |
dc.contributor.author | Kim, Sang-Jin | - |
dc.contributor.author | Jeon, Beom S. | - |
dc.date.accessioned | 2021-09-07T08:38:54Z | - |
dc.date.available | 2021-09-07T08:38:54Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2011-09 | - |
dc.identifier.issn | 1823-6138 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/111620 | - |
dc.description.abstract | Catechol-O-methyltransferase (COMT) inhibitors are used to increase the bioavailability of therapeutic L-dopa. We examined the efficacy of entacapone in Parkinson's disease patients who had daily "off" duration of <= 2 hours, and carried different COMT polymorphisms. A total of 168 PD patients were recruited from 19 centers. Subjects were administered with 100-200 mg of entacapone in combination with each dose of L-dopa for 2 months. The clinical efficacy was evaluated based on the activities of daily living (ADL), score on the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn and Yahr (H&Y) stage, and Clinical Global Impression (CGI). COMT polymorphisms were genotyped. 3-O-methyldopa (3-OMD) levels were measured before and after the administration of entacapone. Entacapone administration produced significant improvements in the total daily "on" duration, ADL, UPDRS score, and H&Y stage. Nineteen patients (11.3%) had the low-activity COMT genotype, 68 patients (40.5%) had the intermediate-activity COMT genotype, and 81patients (48.2%) had the high-activity COMT genotype. The efficacy, and adverse effects of entacapone therapy did not differ between the three groups. There was a significant reduction in 3-OMD, but this did not differ among the three genotypes. Entacapone provided an increased "on" duration and improved motor function in all COMT genotypes. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ASEAN NEUROLOGICAL ASSOC | - |
dc.subject | CATECHOL-O-METHYLTRANSFERASE | - |
dc.subject | LEVODOPA RESPONSE | - |
dc.subject | PHARMACOGENETICS | - |
dc.subject | POLYMORPHISM | - |
dc.subject | INHIBITOR | - |
dc.title | No correlation between COMT genotype and entacapone benefits in Parkinson's disease | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Kun-Woo | - |
dc.identifier.scopusid | 2-s2.0-80053467017 | - |
dc.identifier.wosid | 000295410800006 | - |
dc.identifier.bibliographicCitation | NEUROLOGY ASIA, v.16, no.3, pp.211 - 216 | - |
dc.relation.isPartOf | NEUROLOGY ASIA | - |
dc.citation.title | NEUROLOGY ASIA | - |
dc.citation.volume | 16 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 211 | - |
dc.citation.endPage | 216 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.subject.keywordPlus | CATECHOL-O-METHYLTRANSFERASE | - |
dc.subject.keywordPlus | LEVODOPA RESPONSE | - |
dc.subject.keywordPlus | PHARMACOGENETICS | - |
dc.subject.keywordPlus | POLYMORPHISM | - |
dc.subject.keywordPlus | INHIBITOR | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.